Contract Notice Detail

Summary Information

Summary Information
31/2898/2024 
Medicamento Pertuzumab + Trastuzumab (60+60) + Pertuzumab + Trastuzumab (80+40) [ML/MG; SOL INJ;FRS] 
Tendering Phase
Awarded
31/2898/2024 - Medicamento Pertuzumab + Trastuzumab (60+60) + Pertuzumab + Trastuzumab (80+40) [ML/MG; SOL INJ;FRS] 
VortalGOV - Acquisition under a Framework Agreement (via Direct Award) 
Lot NameLot Base PriceExpected Duration
P1659 - PERTUZUMAB + TRASTUZUMAB [60 + 60 MG/ML; SOL INJ; FRS]-7 (Months)
P1660 - PERTUZUMAB + TRASTUZUMAB [80 + 40 MG/ML; SOL INJ; FRS]-7 (Months)

Object of the Contract

Object of the Contract
Supplies Acquisition 
Rua Leão Penedo 8000-386 União das freguesias de Faro (Sé e São Pedro) Faro PORTUGAL  
33600000-6 - Pharmaceutical products
 
 
 

Scheduling

Scheduling
5/17/2024 11:38 AM (UTC +1 hour)
 
9/4/2023 12:00 AM (UTC +1 hour)
 
5/20/2024 5:00 PM (UTC +1 hour)
 

Financial Settings

Financial Settings
No 

Contract Documents

Contract Documents
Document NameDescriptionDoc Classification
31000028982024.xlsx31000028982024.xlsxDownload
convite 258º.pdfconvite 258º.pdfDownload

Object of contract

No 
No 

Legal, economic, financial and technical information

No 

Questionnaire

Questionnaire
1
Lot Title
P1659 - PERTUZUMAB + TRASTUZUMAB [60 + 60 MG/ML; SOL INJ; FRS]

1.1   Bill of Quantities  *  
This price list has extra requirements. Make sure everything is completed, under each article line.

Item Code Description Quantity Unit
P1659 PERTUZUMAB + TRASTUZUMAB [60 + 60 MG/ML; SOL INJ; FRS] 200,000000 UN
Buyer Comment: 500233810 | Roche - Farmacêutica Química, Lda. | CPA:2023491/150/0379 | NºAIM:5805353;
TOTAL (The amounts shown do not include VAT)
2
Lot Title
P1660 - PERTUZUMAB + TRASTUZUMAB [80 + 40 MG/ML; SOL INJ; FRS]

2.1   Bill of Quantities  *  
This price list has extra requirements. Make sure everything is completed, under each article line.

Item Code Description Quantity Unit
P1660 PERTUZUMAB + TRASTUZUMAB [80 + 40 MG/ML; SOL INJ; FRS] 40,000000 UN
Buyer Comment: 500233810 | Roche - Farmacêutica Química, Lda. | CPA:2023491/150/0380 | NºAIM:5805361;
TOTAL (The amounts shown do not include VAT)

Evaluation

Evaluation
Vision

Avaliação

Definir modelo de avaliação
Modalidade de avaliação
Método de Avaliação
Divulgar critérios de avaliação

Critérios da Avaliação

1 - P1659 - PERTUZUMAB + TRASTUZUMAB [60 + 60 MG/ML; SOL INJ; FRS]

Critérios da Avaliação

Descrição
Tipo de Fator
Peso (%)
1.PricePreço100%

Normas de desempate

Definir normas de desempate?

2 - P1660 - PERTUZUMAB + TRASTUZUMAB [80 + 40 MG/ML; SOL INJ; FRS]

Critérios da Avaliação

Descrição
Tipo de Fator
Peso (%)
1.PricePreço100%

Normas de desempate

Definir normas de desempate?

Public Messages

Public Messages
TypeReferenceSubjectDate
No items found...